.Nature Medicine, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint asks for inclusion of clients with MASLD as well as measurement of liver results in cardio-- renal-- metabolic trials, when data advise mechanistically plausible perks as well as clinical security-- and also summarizes points to consider for trial layout and regulatory commendation.